Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Craig Kessler

Showing results (31-40 of 45) with videos related to

Pageof 5
Sort By:
Haemophilia : the Official Journal of the World Federation of Hemophilia|June 19, 2025
Pain Reduction Following Eptacog Beta Treatment of Bleeding Episodes in Adolescents and Adults With Haemophilia A or B Complicated by InhibitorsTyler W Buckner, Craig Kessler, Giancarlo Castaman, et al.
Leukemia & Lymphoma|January 23, 2019
Phase II trial of Lestaurtinib, a JAK2 inhibitor, in patients with myelofibrosisJohn Mascarenhas, Maria R Baer, Craig Kessler, et al.
Transfusion|August 5, 2005
Fresh frozen plasma prepared with amotosalen HCl (S-59) photochemical pathogen inactivation: transfusion of patients with congenital coagulation factor deficienciesPedro de Alarcon, Richard Benjamin, Marion Dugdale, et al.
The New England Journal of Medicine|July 11, 2017
Emicizumab Prophylaxis in Hemophilia A with InhibitorsJohannes Oldenburg, Johnny N Mahlangu, Benjamin Kim, et al.
Haemophilia : the Official Journal of the World Federation of Hemophilia|November 15, 2018
The effect of emicizumab prophylaxis on health-related outcomes in persons with haemophilia A with inhibitors: HAVEN 1 StudyJohannes Oldenburg, Johnny N Mahlangu, Willem Bujan, et al.
Transfusion|May 11, 2013
Evidence for the continued transmission of parvovirus B19 in patients with bleeding disorders treated with plasma-derived factor concentratesJ Michael Soucie, Paul E Monahan, Roshni Kulkarni, et al.
Transfusion|September 25, 2012
Evidence for the transmission of parvovirus B19 in patients with bleeding disorders treated with plasma-derived factor concentrates in the era of nucleic acid test screeningJ Michael Soucie, Christine De Staercke, Paul E Monahan, et al.
Haemophilia : the Official Journal of the World Federation of Hemophilia|October 22, 2024
A novel gene editing lexicon strategy for the haemophilia community: Research plan for development and preliminary resultsCedric Hermans, Leonard A Valentino, Courtney D Thornburg, et al.
Transfusion|September 28, 2006
A randomized, controlled Phase III trial of therapeutic plasma exchange with fresh-frozen plasma (FFP) prepared with amotosalen and ultraviolet A light compared to untreated FFP in thrombotic thrombocytopenic purpuraPaul D Mintz, Anne Neff, Malcolm MacKenzie, et al.
Blood|September 29, 2021
SARS-CoV-2 vaccination and ITP in patients with de novo or preexisting ITPEun-Ju Lee, Marina Beltrami-Moreira, Hanny Al-Samkari, et al.
Pageof 5

Showing results (31-40 of 45) with videos related to

Sort By:
Pageof 5
Haemophilia : the Official Journal of the World Federation of Hemophilia|June 19, 2025
Pain Reduction Following Eptacog Beta Treatment of Bleeding Episodes in Adolescents and Adults With Haemophilia A or B Complicated by InhibitorsTyler W Buckner, Craig Kessler, Giancarlo Castaman, et al.
Leukemia & Lymphoma|January 23, 2019
Phase II trial of Lestaurtinib, a JAK2 inhibitor, in patients with myelofibrosisJohn Mascarenhas, Maria R Baer, Craig Kessler, et al.
Transfusion|August 5, 2005
Fresh frozen plasma prepared with amotosalen HCl (S-59) photochemical pathogen inactivation: transfusion of patients with congenital coagulation factor deficienciesPedro de Alarcon, Richard Benjamin, Marion Dugdale, et al.
The New England Journal of Medicine|July 11, 2017
Emicizumab Prophylaxis in Hemophilia A with InhibitorsJohannes Oldenburg, Johnny N Mahlangu, Benjamin Kim, et al.
Haemophilia : the Official Journal of the World Federation of Hemophilia|November 15, 2018
The effect of emicizumab prophylaxis on health-related outcomes in persons with haemophilia A with inhibitors: HAVEN 1 StudyJohannes Oldenburg, Johnny N Mahlangu, Willem Bujan, et al.
Transfusion|May 11, 2013
Evidence for the continued transmission of parvovirus B19 in patients with bleeding disorders treated with plasma-derived factor concentratesJ Michael Soucie, Paul E Monahan, Roshni Kulkarni, et al.
Transfusion|September 25, 2012
Evidence for the transmission of parvovirus B19 in patients with bleeding disorders treated with plasma-derived factor concentrates in the era of nucleic acid test screeningJ Michael Soucie, Christine De Staercke, Paul E Monahan, et al.
Haemophilia : the Official Journal of the World Federation of Hemophilia|October 22, 2024
A novel gene editing lexicon strategy for the haemophilia community: Research plan for development and preliminary resultsCedric Hermans, Leonard A Valentino, Courtney D Thornburg, et al.
Transfusion|September 28, 2006
A randomized, controlled Phase III trial of therapeutic plasma exchange with fresh-frozen plasma (FFP) prepared with amotosalen and ultraviolet A light compared to untreated FFP in thrombotic thrombocytopenic purpuraPaul D Mintz, Anne Neff, Malcolm MacKenzie, et al.
Blood|September 29, 2021
SARS-CoV-2 vaccination and ITP in patients with de novo or preexisting ITPEun-Ju Lee, Marina Beltrami-Moreira, Hanny Al-Samkari, et al.
Pageof 5